Ascendis Pharma A/S (NASDAQ:ASND) Stock Price Up 7%

Ascendis Pharma A/S (NASDAQ:ASNDGet Free Report) shares rose 7% on Wednesday . The company traded as high as $131.72 and last traded at $131.40. Approximately 713,567 shares changed hands during trading, an increase of 82% from the average daily volume of 391,167 shares. The stock had previously closed at $122.85.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on the company. Cantor Fitzgerald restated an “overweight” rating and issued a $173.00 price objective on shares of Ascendis Pharma A/S in a research note on Wednesday, May 15th. StockNews.com upgraded Ascendis Pharma A/S from a “sell” rating to a “hold” rating in a research note on Thursday. Wells Fargo & Company upped their price objective on Ascendis Pharma A/S from $260.00 to $262.00 and gave the stock an “overweight” rating in a research note on Friday, May 3rd. Morgan Stanley upped their price objective on Ascendis Pharma A/S from $116.00 to $140.00 and gave the stock an “equal weight” rating in a research note on Thursday, May 16th. Finally, JPMorgan Chase & Co. upped their price objective on Ascendis Pharma A/S from $167.00 to $170.00 and gave the stock an “overweight” rating in a research note on Friday, May 3rd. Two research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $176.88.

Get Our Latest Stock Analysis on Ascendis Pharma A/S

Ascendis Pharma A/S Stock Up 0.7 %

The firm’s fifty day moving average is $140.60 and its two-hundred day moving average is $131.36.

Ascendis Pharma A/S (NASDAQ:ASNDGet Free Report) last issued its earnings results on Thursday, May 2nd. The biotechnology company reported ($2.48) earnings per share for the quarter, missing the consensus estimate of ($1.57) by ($0.91). The firm had revenue of $103.11 million during the quarter, compared to the consensus estimate of $85.72 million. Ascendis Pharma A/S had a negative return on equity of 16,574.15% and a negative net margin of 152.68%. On average, analysts expect that Ascendis Pharma A/S will post -5.03 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Westfield Capital Management Co. LP raised its position in shares of Ascendis Pharma A/S by 1.1% during the 1st quarter. Westfield Capital Management Co. LP now owns 4,075,214 shares of the biotechnology company’s stock valued at $616,050,000 after buying an additional 44,580 shares in the last quarter. Avoro Capital Advisors LLC raised its position in shares of Ascendis Pharma A/S by 5.6% during the 1st quarter. Avoro Capital Advisors LLC now owns 3,966,666 shares of the biotechnology company’s stock valued at $599,641,000 after buying an additional 211,111 shares in the last quarter. Capital International Investors raised its position in shares of Ascendis Pharma A/S by 0.5% during the 1st quarter. Capital International Investors now owns 2,191,312 shares of the biotechnology company’s stock valued at $331,261,000 after buying an additional 10,044 shares in the last quarter. Price T Rowe Associates Inc. MD raised its position in shares of Ascendis Pharma A/S by 23.3% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 1,781,926 shares of the biotechnology company’s stock valued at $269,374,000 after buying an additional 336,976 shares in the last quarter. Finally, Massachusetts Financial Services Co. MA raised its position in shares of Ascendis Pharma A/S by 20.1% during the 4th quarter. Massachusetts Financial Services Co. MA now owns 1,519,219 shares of the biotechnology company’s stock valued at $191,346,000 after buying an additional 254,749 shares in the last quarter.

Ascendis Pharma A/S Company Profile

(Get Free Report)

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.

Featured Articles

Receive News & Ratings for Ascendis Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ascendis Pharma A/S and related companies with MarketBeat.com's FREE daily email newsletter.